Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia.
Eight pediatric patients with fulminant meningococcemia, purpura, and disseminated intravascular cogulation who by multiple prognostic scoring systems were anticipated to have a poor outcome underwent intensive plasma exchange (IPE) or whole blood exchange (WBE) in addition to standard medical therapy. IPE/WBE was initiated shortly after admission with a mixture of both fresh frozen plasma and cryoprecipitate as the replacement solution. All IPE procedures were performed using a continuous flow system and a red cell prime. The mean fibrinogen level increased from 62 to 192 mg/dl, the prothrombin time (PT) decreased from a mean of 32.4 seconds to 15.1 seconds, and the mean activated partial thromboplastin time (APTT) decreased from 89.5 seconds to 40.1 seconds following completion of the initial IPE/WBE. There was a corresponding improvement in all coagulation factor levels but only slight improvement in antithrombin III (ATIII) and protein C levels. Seven of eight patients survived (87.5%) their initial presentation with the sole early death attributed to meningitis with cerebral edema. Mean fluid balance after the procedure was +10.8 +/- 5.87 cc/kg. There were no significant bleeding or cardiovascular complications during the procedure. There was no clinical or radiographic evidence of fluid overload after the procedure. This experience demonstrates that IPE/WBE may be conducted safely in critically ill, unstable pediatric patients and is effective in rapidly improving coagulopathy without fluid overload.
Churchwell
K B
KB
Multidisciplinary intensive Care Unit, Children's Hospital, Boston, Massachusetts 02115, USA.
McManus
M L
ML
Kent
P
P
Gorlin
J
J
Galacki
D
D
Humphreys
D
D
Kevy
S V
SV
D000293:Adolescent; D016470:Bacteremia / Q000209:etiology / Q000628:therapy*; D002675:Child, Preschool; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000628:therapy*; D005078:Exchange Transfusion, Whole Blood / Q000009:adverse effects; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000097:blood* / Q000150:complications / Q000628:therapy; D010951:Plasma Exchange / Q000009:adverse effects; D011693:Purpura / Q000150:complications / Q000628:therapy; D012772:Shock, Septic / Q000209:etiology / Q000628:therapy